Lexaria Bioscience Corp. (NASDAQ: LEXX) to Address
Post# of 421
(Total Views: 285)
Posted On: 09/09/2021 5:10:56 PM
Lexaria Bioscience Corp. (NASDAQ: LEXX) to Address Advances in its Bioavailability Technology DehydraTECH(TM) at Wainwright Life Sciences Conference
- Drug delivery technology innovator Lexaria Bioscience is celebrating the positive outcomes of clinical testing of its trademarked DehydraTECH platform for reducing the blood stream delivery time of anti-virals, NSAIDS and potential hypertension treatments
- Lexaria will participate in H.C. Wainwright’s annual Global Investor Conference this month to help bring further attention to its successes
- The DehydraTECH technology enhances the delivery of pharmaceuticals that can be administered orally, and testing has shown no adverse chemical compounds have been created in the process
- The COVID-19 pandemic has raised the profile of the anti-viral medication market, enhancing the opportunities for Lexaria’s revenue stream
As life sciences technology innovator Lexaria Bioscience (NASDAQ: LEXX) takes a leap forward in R&D programs demonstrating the effectiveness of its trademarked oral substance delivery platform, the company is preparing to join other participants in the 23rd annual Global Investor Conference hosted by full-service investment bank H.C. Wainwright & Co.
The investor conference scheduled Sept. 13-15 will be a hybrid online and in-person gathering of companies enjoying opportunities for platform presentations, one-on-one meetings with investors, and networking with other attendees (https://nnw.fm/ylkFy). Lexaria’s CEO, Chris Bunka, will be making the company’s presentation, which will be available to attendees on Monday September 13th.
Lexaria’s recent strides in developing and testing its oral delivery platform DehydraTECH include its successful 2021 antiviral drug program, which has produced data showing DehydraTECH can enhance antiviral drugs’ ability to reach the bloodstream so that they can safely and more effectively do what they are designed to accomplish.
DehydraTECH processed substances such as pharmaceutical drugs enhance their bioavailability, and the clinical trials have also demonstrated that DehydraTECH does not alter nor degrade the drug molecules chemically as to create new molecular entities (“NMEs”) that would create new regulatory concerns for the finished products (https://nnw.fm/k8LzG).
H.C. Wainwright has a history of leading investment transaction volumes ranked by market research service PlacementTracker. Wainwright has consistently placed first among investment banks for confidentially marketed public offerings, registered direct and private placement transactions, according to the analysts (https://nnw.fm/ZUk2r).
The September event will include a panel discussion with former Food and Drug Administration Commissioner Scott Gottlieb (2017-2019), who is a member of the board of directors of drug maker Pfizer, Inc., and is preparing to roll out his long-awaited book, “Uncontrolled Spread: Why COVID-19 Crushed Us and How We Can Defeat the Next Pandemic,” this month.
The antiviral medication market has gained particular attention during the ongoing COVID-19 pandemic, and Lexaria’s DehydraTECH is in a position to potentially bring in significant revenues in partnership with the antiviral medications as well as NSAIDs and products that target hypertension and alternative nicotine products — an opportunity the company has been mindful of.
The potential for using DehydraTECH in conjunction with cannabidiol (“CBD”) to target hypertension is one of the sectors of Lexaria’s research gaining attention following the results of a recent study showing DehydraTECH-processed CBD generated a rapid and sustained drop in blood pressure among study participants (https://nnw.fm/U6vgi).
“Lexaria was also pleased that its DehydraTECH-CBD was well tolerated by all subjects, with no serious adverse events or side effects observed or reported. Ingestion of the concentration-matched, generic CBD control, on the other hand, resulted in unwanted side effects in some of the volunteers,” the company’s news release states. “These findings corroborate what Lexaria has previously evidenced in other unrelated studies whereby human volunteers have also experienced reduced side effects with DehydraTECH-processed test articles compared to concentration-matched, generic controls.”
A second human clinical hypertension study of DehydraTECH’s capabilities is under way, and a third study is planned this year once the results of the first two studies are carefully evaluated and considered.
For more information, visit the company’s website at www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://nnw.fm/LEXX
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
- Drug delivery technology innovator Lexaria Bioscience is celebrating the positive outcomes of clinical testing of its trademarked DehydraTECH platform for reducing the blood stream delivery time of anti-virals, NSAIDS and potential hypertension treatments
- Lexaria will participate in H.C. Wainwright’s annual Global Investor Conference this month to help bring further attention to its successes
- The DehydraTECH technology enhances the delivery of pharmaceuticals that can be administered orally, and testing has shown no adverse chemical compounds have been created in the process
- The COVID-19 pandemic has raised the profile of the anti-viral medication market, enhancing the opportunities for Lexaria’s revenue stream
As life sciences technology innovator Lexaria Bioscience (NASDAQ: LEXX) takes a leap forward in R&D programs demonstrating the effectiveness of its trademarked oral substance delivery platform, the company is preparing to join other participants in the 23rd annual Global Investor Conference hosted by full-service investment bank H.C. Wainwright & Co.
The investor conference scheduled Sept. 13-15 will be a hybrid online and in-person gathering of companies enjoying opportunities for platform presentations, one-on-one meetings with investors, and networking with other attendees (https://nnw.fm/ylkFy). Lexaria’s CEO, Chris Bunka, will be making the company’s presentation, which will be available to attendees on Monday September 13th.
Lexaria’s recent strides in developing and testing its oral delivery platform DehydraTECH include its successful 2021 antiviral drug program, which has produced data showing DehydraTECH can enhance antiviral drugs’ ability to reach the bloodstream so that they can safely and more effectively do what they are designed to accomplish.
DehydraTECH processed substances such as pharmaceutical drugs enhance their bioavailability, and the clinical trials have also demonstrated that DehydraTECH does not alter nor degrade the drug molecules chemically as to create new molecular entities (“NMEs”) that would create new regulatory concerns for the finished products (https://nnw.fm/k8LzG).
H.C. Wainwright has a history of leading investment transaction volumes ranked by market research service PlacementTracker. Wainwright has consistently placed first among investment banks for confidentially marketed public offerings, registered direct and private placement transactions, according to the analysts (https://nnw.fm/ZUk2r).
The September event will include a panel discussion with former Food and Drug Administration Commissioner Scott Gottlieb (2017-2019), who is a member of the board of directors of drug maker Pfizer, Inc., and is preparing to roll out his long-awaited book, “Uncontrolled Spread: Why COVID-19 Crushed Us and How We Can Defeat the Next Pandemic,” this month.
The antiviral medication market has gained particular attention during the ongoing COVID-19 pandemic, and Lexaria’s DehydraTECH is in a position to potentially bring in significant revenues in partnership with the antiviral medications as well as NSAIDs and products that target hypertension and alternative nicotine products — an opportunity the company has been mindful of.
The potential for using DehydraTECH in conjunction with cannabidiol (“CBD”) to target hypertension is one of the sectors of Lexaria’s research gaining attention following the results of a recent study showing DehydraTECH-processed CBD generated a rapid and sustained drop in blood pressure among study participants (https://nnw.fm/U6vgi).
“Lexaria was also pleased that its DehydraTECH-CBD was well tolerated by all subjects, with no serious adverse events or side effects observed or reported. Ingestion of the concentration-matched, generic CBD control, on the other hand, resulted in unwanted side effects in some of the volunteers,” the company’s news release states. “These findings corroborate what Lexaria has previously evidenced in other unrelated studies whereby human volunteers have also experienced reduced side effects with DehydraTECH-processed test articles compared to concentration-matched, generic controls.”
A second human clinical hypertension study of DehydraTECH’s capabilities is under way, and a third study is planned this year once the results of the first two studies are carefully evaluated and considered.
For more information, visit the company’s website at www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://nnw.fm/LEXX
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)